A Case Report and Literature Review of Antibody Conjugated Drugs for Parotid Ductal Adenocarcinoma

Abstract

Salivary ductal carcinoma (SDC) is a rare highly aggressive malignancy with unique pathological and clinical features, and its histological features are highly similar to that of breast ductal carcinoma. The standard treatment for SDC is surgery plus radiation therapy, but it is often detected late and has a poor prognosis. Human growth factor receptor 2 (HER2) overexpression is common in SDC, and HER2-positive SDC cases have strong aggressiveness, and the standard treatment regimen for patients with postoperative recurrence or metastasis is still controversial. Vedicitumab is an innovative antibody coupling drug independently developed in China. It targets HER2 protein on the tumor surface and can accurately identify and kill tumor cells. This case reports a case of HER2 positive SDC treated with vidiximab alone, which has a rapid onset and significant effect. It may be a promising research direction for the treatment of this disease, but the sample size control study needs to be further expanded.